According to filings with the U.S. Securities and Exchange Commission, Tavo Biotherapeutics has raised $17 Million in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Pureos Bioventures, Polaris Partners, and Tau Capital

About Tavo Biotherapeutics
Tavo Biotherapeutics is focused on developing novel therapeutics aimed at addressing significant unmet medical needs in ophthalmology, with a particular emphasis on preserving vision and improving long-term outcomes for patients with glaucoma and retinal disease. TAV-001 is being studied as a potential disease-modifying topical therapy for the treatment of glaucoma. TAV-001 utilizes a dual mode of action that targets the autonomic nervous system, which drives the mechanisms that cause inflammation and degeneration in glaucoma. The program is moving into a Phase 2 clinical trial in the second half of 2026. TAV-002 is a bispecific antibody that targets both VEGF and a protein involved in upstream signaling in serious retinal diseases, including both wet and dry forms of age-related macular degeneration as well as diabetes-related retinopathies.

To learn more, visit https://tavobio.com/
Linkedin: https://www.linkedin.com/company/tavo-bio/

Contact:
Gary Berman, Chief Executive Officer
https://www.linkedin.com/in/gary-berman-a86bbb/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.